| Market Cap | 22.47M | P/E | - | EPS this Y | 19.40% | Ern Qtrly Grth | - |
| Income | -8.89M | Forward P/E | -1.03 | EPS next Y | -116.00% | 50D Avg Chg | -6.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -8.00% |
| Dividend | N/A | Price/Book | 2.23 | EPS next 5Y | - | 52W High Chg | -60.00% |
| Recommedations | 2.00 | Quick Ratio | 10.10 | Shares Outstanding | 35.48M | 52W Low Chg | 65.00% |
| Insider Own | 20.07% | ROA | -44.65% | Shares Float | 24.89M | Beta | 1.71 |
| Inst Own | 10.47% | ROE | -80.30% | Shares Shorted/Prior | 89.94K/8.09K | Price | 0.78 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 27,970 | Target Price | 10.00 |
| Oper. Margin | - | Earnings Date | May 3 | Volume | 7,416 | Change | -0.01% |
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| HC Wainwright & Co. | Buy | Apr 2, 24 |
| HC Wainwright & Co. | Buy | Dec 11, 23 |
| HC Wainwright & Co. | Buy | Sep 13, 23 |
| HC Wainwright & Co. | Buy | Sep 11, 23 |
| HC Wainwright & Co. | Buy | May 8, 23 |
| HC Wainwright & Co. | Buy | Apr 4, 23 |
| HC Wainwright & Co. | Buy | Mar 28, 23 |
| HC Wainwright & Co. | Buy | Sep 6, 22 |
| B. Riley Securities | Buy | Jul 19, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Taitel Haya | Director Director | Jan 12 | Buy | 0.99 | 9,500 | 9,405 | 35,115 | 01/16/24 |
| Taitel Haya | Director Director | Jan 10 | Buy | 0.77 | 7,615 | 5,864 | 25,615 | 01/11/24 |
| LIEBERMAN GERALD M | Director Director | Dec 22 | Buy | 0.71 | 23,952 | 17,006 | 226,961 | 12/27/23 |
| Toledano Miranda Jayne | Chief Executive Offi.. Chief Executive Officer | Dec 22 | Buy | 0.71 | 23,952 | 17,006 | 110,752 | 12/27/23 |
| Taitel Haya | Director Director | Aug 22 | Buy | 0.6231 | 18,000 | 11,216 | 18,000 | 08/24/23 |
| LIEBERMAN GERALD M | Director Director | Aug 21 | Buy | 0.5892 | 20,000 | 11,784 | 214,209 | 08/23/23 |
| Ellis Sean | Director Director | Jul 21 | Buy | 1.638 | 14,900 | 24,406 | 32,100 | 07/25/22 |
| LIEBERMAN GERALD M | Director Director | Jul 21 | Buy | 1.683 | 19,491 | 32,803 | 160,209 | 07/25/22 |
| OSTROV GERALD M | Director Director | Jan 13 | Buy | 2.7378 | 10,000 | 27,378 | 10,000 | 01/25/22 |
| Ratan Ramesh | U.S.based CFO U.S.based CFO | Jan 19 | Buy | 2.4364 | 10,000 | 24,364 | 10,000 | 01/24/22 |
| JAMAS SPIROS | Chief Executive Offi.. Chief Executive Officer | Jan 18 | Buy | 2.85 | 10,000 | 28,500 | 10,000 | 01/24/22 |
| Schwartz Phillip | President of R&D President of R&D | Jan 20 | Buy | 2.525 | 10,000 | 25,250 | 607,410 | 01/24/22 |
| LIEBERMAN GERALD M | Director Director | Jan 18 | Buy | 2.8 | 2,800 | 7,840 | 2,200 | 01/24/22 |